Skip to contentN
Niagen Bioscience, Inc.
N
NAGENiagen Bioscience, Inc. Q3 2016 · 10-Q
Revenue$3.94M$3.94M−37.4% vs Q3 2015 Net Income-$954.39K-$954.39KN/M vs Q3 2015 EPS Diluted-$0.03-$0.03— vs Q3 2015 Gross Profit$2,042,470−17.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Niagen Bioscience, Inc. · CIK 1386570 · Engraved from SEC EDGAR
Operating Cash Flowderived-$140,395— Free Cash Flowderived-$850,172N/M Margins · derivedGross margin51.9%+12.4 pt vs Q3 2015
Operating margin-24.0%−26.9 pt vs Q3 2015
Net margin-24.2%−24.2 pt vs Q3 2015
ended Oct 1, 2016 · filed Nov 10, 2016 · 40 d after period end